Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New Two-Drug attack on tough lung cancer

NCT ID NCT03527108

Summary

This study is testing whether combining two existing drugs, nivolumab and ramucirumab, can better control advanced lung cancer that has come back after prior treatment. It will enroll about 36 adults who have already tried at least one other therapy. The main goal is to see if this combination can stop the cancer from growing, shrink it, or make it disappear for a period of time.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • NYU Langone

    New York, New York, 10016, United States

Conditions

Explore the condition pages connected to this study.